: Specialized building blocks for drug synthesis, such as 2-Methyl-4-Amino Benzoic acid and 4-Methoxy Benzaldehyde dimethyl acetal .
Hypersynth's catalog includes over 40 distinct chemical and pharmaceutical categories. hypersynth life sciences
Hypersynth is currently embroiled in a patent dispute with the Broad Institute over the rights to "AI-generated genetic circuits." The question before the courts is: If an algorithm invents a gene, who owns it? Hypersynth argues they are the "authors of the AI," while traditionalists argue that non-human inventors cannot be listed on patents. This litigation will likely define the legal landscape for the next decade. : Specialized building blocks for drug synthesis, such
Critics argue that the "Generative Genomics Engine" is a dual-use technology of concern. If an AI can design a novel enzyme to degrade plastic, it can also design a novel toxin or a hyper-virulent pathogen. Hypersynth claims to have implemented "guardrails" in their software—filtering outputs that match known virulence factors or toxin scaffolds. However, academic bioethicists at the Harvard Wyss Institute counter that "novel threats" by definition won't be caught by filters looking for known threats. Hypersynth argues they are the "authors of the
